Drug
Intermediate risk with partial remission after two cycles of ABVD chemotherapy schedule. Four more chemotherapy courses are delivered alternating ESHAP and ABVD.
Intermediate risk with partial remission after two cycles of ABVD chemotherapy schedule. Four more chemotherapy courses are delivered alternating ESHAP and ABVD. is a pharmaceutical drug with 1 clinical trials. Currently 1 active trials ongoing.
Total Trials
1
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Active Trials
1(100%)
Phase Distribution
Ph phase_4
1
100%
Phase Distribution
0
Early Stage
0
Mid Stage
1
Late Stage
Phase Distribution1 total trials
Phase 4Post-market surveillance
1(100.0%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
1
all time
Status Distribution
Active(1)
Detailed Status
Recruiting1
Development Timeline
Analytics
Development Status
Total Trials
1
Active
1
Success Rate
N/A
Most Advanced
Phase 4
Trials by Phase
Phase 41 (100.0%)
Trials by Status
recruiting1100%
Recent Activity
Clinical Trials (1)
Showing 1 of 1 trials
All 1 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 1